A Phase 3 interventional study of Selexipag in Hypertension, Pulmonary, sponsored by Actelion. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Hypertension, Pulmonary by Johnson & Johnson — 1 open to participants now, 2 under way, 2 of them phase 3. Hypertension, Pulmonary · Johnson & Johnson.
Among the 29 studies in Hypertension, Pulmonary by Johnson & Johnson, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2021, is one of 13 in phase 3, and was the 28th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →1 of the 29 studies in Hypertension, Pulmonary by Johnson & Johnson is open now, in 12 countries. Recruiting first, the newest first:
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is above the median of 35 across 649 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 67 across the 27 interventional studies, 2,003 across the 2 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
1 of the studies in Hypertension, Pulmonary by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Hypertension, Pulmonary by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the long-term safety of selexipag while providing continued selexipag treatment for participants who were previously enrolled in an Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications for which a positive benefit-risk has been established.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive selexipag tablets twice daily with the dose strength corresponding to their individual maximum tolerated dose (iMTD) from the parent study.
Drug: Selexipag
Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily.
Also known as: JNJ-67896049, ACT-293987
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs were reported. Adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days. Data includes all TEAEs irrespective of whether they were serious or non-serious.
Time frame: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)
Number of Participants With TEAEs Leading to Premature Discontinuation of Selexipag
Number of participants with TEAEs leading to premature discontinuation of selexipag were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days.
Time frame: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Number of participants with TESAEs were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TESAEs were defined as TSAEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days.
Time frame: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)
Number of Participants With Treatment-emergent Deaths
Number of participants with treatment-emergent deaths during the study were reported.
Time frame: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days)
Number of Pregnant Females With Maternal Exposure to Selexipag
Number of pregnant females with maternal exposure to selexipag were reported.
Time frame: From Day 1 up to 30 days after last dose of drug (up to 29 months)
| Milestone | Selexipag |
|---|---|
| Started | 43 |
| Completed | 36 |
| Not completed | 7 |
| Withdrew: Death | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 1 |
Number of participants with TEAEs were reported. Adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days. Data includes all TEAEs irrespective of whether they were serious or non-serious.
| Participants | Selexipag |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 22 |
Number of participants with TEAEs leading to premature discontinuation of selexipag were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days.
| Participants | Selexipag |
|---|---|
| Number of Participants With TEAEs Leading to Premature Discontinuation of Selexipag | 0 |
Number of participants with TESAEs were reported. AE was defined as any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TESAEs were defined as TSAEs occurring at or after the initial administration of study intervention through the day of last dose plus 3 days.
| Participants | Selexipag |
|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | 7 |
Number of participants with treatment-emergent deaths during the study were reported.
| Participants | Selexipag |
|---|---|
| Number of Participants With Treatment-emergent Deaths | 5 |
Number of pregnant females with maternal exposure to selexipag were reported.
| Participants | Selexipag |
|---|---|
| Number of Pregnant Females With Maternal Exposure to Selexipag | 0 |
Collected over All cause mortality: From Day 1 up to 30 days after last dose of drug (up to 29 months), Other AEs and SAEs: From Day 1 up to 3 days after last dose of drug (up to 28 months 3 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selexipag | 5/43 (11.6%) | 7/43 (16.3%) | 20/43 (46.5%) |
| Event | Selexipag |
|---|---|
| Pulmonary Arterial HypertensionRespiratory, thoracic and mediastinal disorders | 3/43 |
| Cardiac Failure AcuteCardiac disorders | 1/43 |
| Covid-19 PneumoniaInfections and infestations | 1/43 |
| PneumoniaInfections and infestations | 1/43 |
| Subacute EndocarditisInfections and infestations | 1/43 |
| SyphilisInfections and infestations | 1/43 |
| Systemic SclerodermaMusculoskeletal and connective tissue disorders | 1/43 |
| HypotensionVascular disorders | 1/43 |
| Event | Selexipag |
|---|---|
| Covid-19Infections and infestations | 4/43 |
| Chronic GastritisGastrointestinal disorders | 2/43 |
| PyrexiaGeneral disorders | 2/43 |
| Respiratory Tract InfectionInfections and infestations | 2/43 |
| AnaemiaBlood and lymphatic system disorders | 1/43 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/43 |
| Atrial FibrillationCardiac disorders | 1/43 |
| Pericardial EffusionCardiac disorders | 1/43 |
| Sinus TachycardiaCardiac disorders | 1/43 |
| GoitreEndocrine disorders | 1/43 |
| Age, Continuous(years) | Selexipag |
|---|---|
| Mean | 50.6 ± 13.25 |
| Age, Customized(Participants) | Selexipag |
|---|---|
| Adults (18-64 years) | 37 |
| From 65 to 84 years | 6 |
| >=85 years | 0 |
| Sex: Female, Male(Participants) | Selexipag |
|---|---|
| Female | 36 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | Selexipag |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 43 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Selexipag |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 11 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 32 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Selexipag |
|---|---|
| BELARUS | 21 |
| INDIA | 4 |
| ROMANIA | 2 |
| SOUTH KOREA | 4 |
| TAIWAN | 3 |
| UKRAINE | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from May 2021 to primary completion in Nov 2023, 30 months.
Results were first posted in Nov 2024, 1 year after primary completion.
Of 31 phase 3 interventional studies under Hypertension, Pulmonary, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 83. This study's 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag